Jump to content

Template:Oral hypoglycemics and insulin analogs

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 06:53, 20 December 2023 (add Metformin/teneligliptin, Sitagliptin/dapagliflozin). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

To change this template's initial visibility, the |state= parameter may be used:

  • {{Oral hypoglycemics and insulin analogs|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
  • {{Oral hypoglycemics and insulin analogs|state=expanded}} will show the template expanded, i.e. fully visible.